Aytu BioPharma (NASDAQ:AYTU) Downgraded by Zacks Research to “Strong Sell”

Aytu BioPharma (NASDAQ:AYTU) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday,Zacks.com reports.

A number of other equities research analysts have also issued reports on AYTU. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Ascendiant Capital Markets boosted their target price on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Aytu BioPharma presently has an average rating of “Hold” and a consensus price target of $10.75.

Aytu BioPharma Price Performance

Shares of Aytu BioPharma stock opened at $2.16 on Wednesday. The company has a market capitalization of $23.18 million, a price-to-earnings ratio of -0.47 and a beta of 0.24. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27. The stock’s 50-day simple moving average is $2.20 and its 200-day simple moving average is $2.44. Aytu BioPharma has a 52 week low of $1.65 and a 52 week high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The business had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million. As a group, analysts expect that Aytu BioPharma will post -0.73 earnings per share for the current fiscal year.

Institutional Trading of Aytu BioPharma

Several hedge funds have recently made changes to their positions in the business. Arete Wealth Advisors LLC bought a new position in shares of Aytu BioPharma in the 1st quarter valued at about $135,000. Rothschild Wealth LLC bought a new stake in Aytu BioPharma during the fourth quarter worth approximately $52,000. Dimensional Fund Advisors LP purchased a new stake in Aytu BioPharma during the third quarter valued at approximately $58,000. Diadema Partners LP raised its position in Aytu BioPharma by 12.1% during the fourth quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock valued at $795,000 after purchasing an additional 33,118 shares during the period. Finally, Persistent Asset Partners Ltd lifted its stake in shares of Aytu BioPharma by 27.2% in the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after purchasing an additional 16,963 shares during the last quarter. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.